Actavis to launch generic ADHD drug in December 2014
PARSAPPANY, N.J. — Actavis can launch a generic version of an attention deficit hyperactivity disorder drug made by Shire next year under an agreement between the two companies announced Thursday.
The drug makers said they settled a patent-litigation suit concerning the drug Intuniv (guanfacine hydrochloride), allowing Actavis to launch in December 2014 and also settling outstanding litigation against a regulatory filing by Actavis predecessor Watson for Food and Drug Administration approval of a generic version of the drug. The FDA approved Actavis’ version of the drug in October 2012 and, as the first company to file a complete application with the agency, Actavis is entitled to 180 days of market exclusivity in which to compete directly with the branded version after launching it.
Under the deal with Shire, Shire will receive a 25% royalty on Actavis’ gross profits from the drug.
Intuniv had sales of about $475 million during the 12-month period that ended in January, according to IMS Health.
Cardinal Health, McKesson renew pharmaceutical distribution agreements with CVS Caremark
DUBLIN, Ohio — Cardinal Health and McKesson separately announced the renewal of their pharmaceutical distribution agreements with CVS Caremark.
Under Cardinal Health’s renewed agreement, the wholesaler stated that it will supply pharmaceuticals to a network of CVS Caremark’s retail pharmacies and distribution centers through mid-2016. The stores and distribution centers serviced under the new arrangement are essentially the same as those serviced in the prior arrangement.
"CVS Caremark has been a long and valued partner to Cardinal Health. We are excited to continue to build on that tradition. We look forward to working together to create value for our evolving heathcare system," stated George Barrett, chairman and CEO of Cardinal Health.
Meanwhile, McKesson, which generally serves the PBM side of the business, also has announced the renewal of its current distribution agreement with CVS Caremark.
“We are extremely pleased to continue our long standing relationship with CVS Caremark,” stated Paul Julian, EVP and group president of McKesson. “McKesson’s comprehensive supply chain solutions continue to help CVS Caremark ensure the highest levels of product availability and product integrity, empowering CVS Caremark to provide outstanding pharmaceutical care to its customers.”
New product launches help fuel Colgate’s U.S. sales, market share in Q1
NEW YORK — Colgate announced on Thursday that North American net sales rose 5.5% as new product launches, such as Colgate Optic White mouthwash, helped drive volume growth and market share gains in the United States.
North America, which accounts for 18% of company sales, posted a net sales increase of 5.5%. Organic sales also rose 5.5% during the quarter.
In the U.S., market share gains were seen in manual toothbrush, powered toothbrushes, mouthwash, body washes and fabric conditioners. In toothpaste, the company noted the success of Colgate Optic White and Colgate Optic White Dual Action toothpastes, which helped drive market share for the Optic White brand to 5.7% year to date, up 1.3 share points versus a year ago.
In manual toothbrushes, Colgate’s market share reached a record 37.1% year to date, up 0.3 share points versus a year ago, driven by the success of Colgate 360 Optic White, Colgate 360 Total Advanced Floss Tip bristles and Colgate Extra Clean manual toothbrushes, the company stated.
New product launches for the second quarter 2013 include Colgate Advanced Pro-Shield mouthwash, which is an addition to the Colgate Total oral care regimen. The launch will be supported by an integrated marketing campaign featuring television personality Kelly Ripa as the new spokesperson for the Colgate Total brand.
On a global basis, the company posted net sales of $4.32 billion, up 2.5% compared with the year-ago period. Organic sales grew 6%.
Net income and diluted earnings per share in the quarter were $593 million and $1.23, respectively. Excluding certain items, net income in the quarter totaled $626 million, an increase of 4% compared with the year-ago period, and diluted earnings per share were $1.32, an increase of 6%.
“Colgate’s global market share in toothbrushes and manual toothbrushes are both at record highs year to date. Colgate’s share of the global toothpaste market strengthened to 45.6% year to date, up 0.1 share points versus year ago. Our global leadership in manual toothbrushes also strengthened during the quarter with Colgate’s global market share in that category reaching 33.4% year to date, up 0.4 share points versus year ago,” said Ian Cook, chairman, president and CEO.